$PRQR News

ProQR Therapeutics To Present Data On Its AX-0810, AX-0811 At The Liver Meeting 2026, Nature Conferences RNA

ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease

HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - Slideshow

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

ProQR to Participate in Upcoming Investor Conferences in September 2026

B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8

ProQR Announces Second Quarter 2026 Operating and Financial Results

ProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M Estimate

ProQR Form4 Filing Shows CEO Daniel De Boer Buys 200,000 Shares At An Average Price Of $1.77; Increasing Direct Holdings to 500,000 Shares

ProQR Therapeutics Files Prospectus For Offering 3.03M Ordinary Shares On Behalf Of Selling Shareholder

ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis

Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

ProQR Therapeutics Announces Data From Its Ongoing Phase 1 Clinical Study Of AX-0810 Investigational Axiomer RNA Editing Oligonucleotide; Sees Target Engagement On All Key Biomarkers

ProQR Therapeutics N.V. (PRQR) Presents at 29th ASGCT Annual Meeting 2026 - Slideshow

ProQR Therapeutics N.V. (PRQR) Presents at TIDES USA 2026 - Slideshow

ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%